Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: An EORTC Gynaecological Cancer Cooperative Group Study

M. E L van der Burg, S. Monfardini, J. P. Guastalla, C. de Oliveira, J. Renard, J. B. Vermorken

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4′-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.

Original languageEnglish
Pages (from-to)147-148
Number of pages2
JournalEuropean Journal of Cancer
Volume29
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

Squamous Cell Neoplasms
Epirubicin
Uterine Cervical Neoplasms
Neoplasms
Cervix Uteri
Disease Progression
Squamous Cell Carcinoma
Appointments and Schedules
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix : An EORTC Gynaecological Cancer Cooperative Group Study. / van der Burg, M. E L; Monfardini, S.; Guastalla, J. P.; de Oliveira, C.; Renard, J.; Vermorken, J. B.

In: European Journal of Cancer, Vol. 29, No. 1, 1993, p. 147-148.

Research output: Contribution to journalArticle

van der Burg, M. E L ; Monfardini, S. ; Guastalla, J. P. ; de Oliveira, C. ; Renard, J. ; Vermorken, J. B. / Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix : An EORTC Gynaecological Cancer Cooperative Group Study. In: European Journal of Cancer. 1993 ; Vol. 29, No. 1. pp. 147-148.
@article{9bfb7ccb12014d22b15eaf2427780389,
title = "Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: An EORTC Gynaecological Cancer Cooperative Group Study",
abstract = "In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4{\%}) had a partial remission lasting 23 weeks and 9 patients (38{\%}) had stable disease with a median duration of 13 weeks (range 7-36). 4′-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.",
author = "{van der Burg}, {M. E L} and S. Monfardini and Guastalla, {J. P.} and {de Oliveira}, C. and J. Renard and Vermorken, {J. B.}",
year = "1993",
doi = "10.1016/0959-8049(93)90596-8",
language = "English",
volume = "29",
pages = "147--148",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix

T2 - An EORTC Gynaecological Cancer Cooperative Group Study

AU - van der Burg, M. E L

AU - Monfardini, S.

AU - Guastalla, J. P.

AU - de Oliveira, C.

AU - Renard, J.

AU - Vermorken, J. B.

PY - 1993

Y1 - 1993

N2 - In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4′-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.

AB - In this study 24 patients with metastatic cervical cancer were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12.5 mg/m2. All patients were followed until disease progression. Toxicity was generally absent or very mild. Only 1 patient (4%) had a partial remission lasting 23 weeks and 9 patients (38%) had stable disease with a median duration of 13 weeks (range 7-36). 4′-Epidoxorubicin at this dose and schedule is not active in metastatic squamous cell carcinoma of the cervix.

UR - http://www.scopus.com/inward/record.url?scp=0027420207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027420207&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(93)90596-8

DO - 10.1016/0959-8049(93)90596-8

M3 - Article

C2 - 1280152

AN - SCOPUS:0027420207

VL - 29

SP - 147

EP - 148

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -